PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Baloxavir Marboxil→

Baloxavir Marboxil PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1985606-14-1
Molecular formula
C27H23F2N3O7S
Molecular weight
571.6 g/mol
Drug class
Antiviral prodruginfluenza virus cap-dependent endonuclease inhibitor precursor
Mechanism of action
Baloxavir marboxil is converted to baloxavir acid, which inhibits the cap-dependent endonuclease of the influenza virus polymerase acidic (PA) protein, preventing viral mRNA synthesis and replication.
Indications / reported uses
  • Treatment of acute uncomplicated influenza in patients aged 5 years and older who are otherwise healthy or at high risk of influenza complications under the US label
  • Post-exposure prophylaxis of influenza in eligible patients aged 5 years and older; product- and jurisdiction-specific

Sources: US DailyMed — XOFLUZA · FDA — XOFLUZA label · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Baloxavir Marboxil PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Baloxavir Marboxil Permitted Daily Exposure (PDE) report (the Baloxavir Marboxil PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Baloxavir Marboxil Occupational Exposure Limit (OEL) report (the Baloxavir Marboxil OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.